Immuneering Corporation (IMRX)
| Market Cap | 316.37M +603.3% |
| Revenue (ttm) | n/a |
| Net Income | -54.44M |
| EPS | -0.84 |
| Shares Out | 64.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 696,756 |
| Open | 4.910 |
| Previous Close | 4.870 |
| Day's Range | 4.810 - 4.930 |
| 52-Week Range | 1.400 - 10.080 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+247.65%) |
| Earnings Date | May 15, 2026 |
About IMRX
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for IMRX stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 247.65% from the latest price.
News
Immuneering reports Q1 EPS (21c), consensus (25c)
“We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral…
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal P...
Immuneering Earnings release: Q1 2026
Immuneering released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Immuneering Quarterly report: Q1 2026
Immuneering has published its Q1 2026 quarterly earnings report on May 15, 2026.
Immuneering announces updated data from Phase 2a trial for atebimetinib
Immuneering (IMRX) Corporation announced that updated data from the Phase 2a clinical trial evaluating atebimetinib, IMM-1-104, in combination with modified gemcitabine/nab-paclitaxel in first-line pa...
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -
Immuneering announces presentation of new genetic data at 2026 AACR
Immuneering (IMRX) announced the presentation of new genetic data at the 2026 American Association for Cancer Research, AACR, Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Key…
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarel...
Immuneering Proxy statement: Proxy filing
Immuneering filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Immuneering Proxy statement: Proxy filing
Immuneering filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference
Atebimetinib demonstrated a 64% 12-month overall survival in first-line pancreatic cancer, with robust tolerability and unique mechanisms supporting both efficacy and quality of life. The pivotal phase III trial is set to begin dosing mid-year, with a top-line OS readout expected in about two years.
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability
Immuneering Transcript: Leerink Global Healthcare Conference 2026
Deep Cyclic Inhibitors, led by atebimetinib, show promising survival and tolerability in First-Line pancreatic cancer, with 64% 12-month survival and minimal added toxicity. A pivotal phase III trial is launching, and combination studies in lung cancer are planned.
Immuneering price target lowered to $12 from $13 at Piper Sandler
Piper Sandler lowered the firm’s price target on Immuneering (IMRX) to $12 from $13 and keeps an Overweight rating on the shares following the company’s Q4 update. Timing for near-term…
Immuneering Annual report: Q4 2025
Immuneering has published its Q4 2025 annual report on March 6, 2026.
Immuneering Earnings release: Q4 2025
Immuneering released its Q4 2025 earnings on March 6, 2026, summarizing the period's financial results.
Immuneering reports Q4 EPS (18), consensus (31c)
“2025 was a transformative year for Immuneering (IMRX). We reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP, well above the benchmar...
Immuneering sees cash runway into 2029
Cash, cash equivalents and marketable securities as of December 31, 2025 were $217.0 million, compared with $36.1 million as of December 31, 2024.
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overal...
Immuneering to Present at the Leerink Global Healthcare Conference
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...
Immuneering Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Atebimetinib, a novel Deep Cyclic Inhibitor, demonstrated 64% 12-month survival in first-line pancreatic cancer, nearly doubling standard benchmarks. A global Phase III trial will begin mid-year, with expanded cohort data expected in 2026, and strong enthusiasm from investigators and KOLs.
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today annou...
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
After Immuneering (IMRX) announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancre...
Immuneering reports ‘positive’ survival, safety data from atebimetinib trial
Immuneering (IMRX) announced positive updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pan...